A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Surgical resection remains a mainstay in the treatment of malignant solid tumors. However,
the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy …

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor
with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple …

Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …

Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs)
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …

The durable response rate to immune checkpoint blockade such as anti-programmed cell
death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly …

Immune checkpoint blockade (ICB) has shown significant clinical success, yet its responses
can vary due to immunosuppressive tumor microenvironments. To enhance antitumor …

The last decade of microbiome research has highlighted its fundamental role in systemic
immune and metabolic homeostasis. The microbiome plays a prominent role during …

Immunotherapy especially immune checkpoint inhibitors (ICIs) has brought favorable clinical
results for numerous cancer patients. However, the efficacy of ICIs in colorectal cancer …

Adjuvants play an important role in enhancing vaccine‐induced immune protection.
Adequate cellular uptake, robust lysosomal escape, and subsequent antigen cross …